THERAPEUTIC INDIUM 111 PENTETREOTIDE IN SOMATOSTAIN RECEPTOR EXPRESSING CANCERS

表达癌症的生长抑素受体中的治疗性铟 111 戊曲肽

• 批准号: 6298329
• 负责人: LOWELL B ANTHONY
• 金额: $ 1.97万
• 依托单位: TULANE UNIVERSITY OF LOUISIANA
• 依托单位国家: 美国
• 财政年份: 1997
• 资助国家: 美国
• 起止时间: 1997-12-01 至 1999-06-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6298329
• 关键词: blood chemistry; clinical research; clinical trial phase I; drug screening /evaluation; hormone receptor; human subject; human therapy evaluation; indium; intravenous administration; neoplasm /cancer radionuclide therapy; peptide hormone analog; radiation dosage; radionuclide imaging /scanning; radionuclides; radiopharmacology; receptor expression; somatostatin; urinalysis

This study is to evaluate the safety and efficacy of Indium 111 pentetreotide in high doses (180mci) for treatment of somatostatin expressing neoplasms which are resistant to or have failed standard therapy. The subjects will receive this radioactive-somatostatin analog, normally used for scanning in low doses, intravenously with subsequent dosimetry to assess the body's response to the new agent. Blood work and urine collections will be done to provide information about the levels of radioactivity remaining in the body. The patient will also be seen in the nuclear medicine department for scanning to assess radioactive levels.

本研究旨在评价铟111的安全性和有效性 大剂量喷替曲肽治疗生长抑素 表达对标准有抵抗力或不合格的肿瘤 疗法受试者将接受这种放射性生长抑素类似物， 通常用于低剂量扫描，静脉注射，随后 剂量测定法来评估身体对新制剂的反应。血液检查和 将进行尿液收集，以提供有关水平的信息 残留在体内的放射性物质患者也将在 核医学部进行扫描，以评估放射性 程度.